Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 02 - 24    symbols : BLUE    save search
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
Published: 2021-02-24 (Crawled : 00:00) - biospace.com/
BMY | $48.86 -0.27% 1.0% 14M twitter stocktwits trandingview |
Health Technology
 | | O: 0.3% H: 3.32% C: 2.78%
BLUE | $0.9229 -4.91% -4.66% 7.9M twitter stocktwits trandingview |
Health Technology
 | | O: 2.65% H: 1.48% C: -1.44%
phase 2 therapy results t-cell car-t cel
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M twitter stocktwits trandingview |
Consumer Services
BOF | $2.08 77.78% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.54 12.27% 40.62% 3.7M twitter stocktwits trandingview |

LICN | $0.999 78.39% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.4 70.0% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.458 14.5% 30.92% 91K twitter stocktwits trandingview |
Health Services
MULN | News | $3.77 38.1% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.75 36.97% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.